ALEMBIC PHARMACEUTICALS LTD.

Alembic Pharmaceuticals Ltd has announced the incorporation of its wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai, United Arab Emirates. The subsidiary was incorporated on August 24, 2026, with an initial investment of AED 100,000. Its primary objective is to explore new business opportunities and promote, sell, and distribute the company's pharmaceutical products in the region. This move signifies Alembic Pharma's strategic expansion into international markets to enhance its global presence and sales network.

Alembic Pharmaceuticals reported a resilient Q1 FY27 performance with a 26% year-on-year increase in revenue from operations, reaching ₹2150 Cr. Profit After Tax (PAT) grew by 12% YoY to ₹173 Cr. EBITDA pre-R&D stood at ₹523 Cr, with a margin of 24%. The company saw strong growth in its US Formulation business, up 49% to ₹778 Cr, and a 33% rise in its API business to ₹346 Cr. The India Branded Business grew 7% YoY to ₹642 Cr. Management highlighted broad-based growth driven by volume, new product launches, and execution across key markets. The company also received 10 ANDA approvals and launched 7 new products in the US market during the quarter.

Alembic Pharmaceuticals reported a resilient Q1 FY27 performance with consolidated revenue from operations increasing by 26% year-on-year to ₹2150 Cr. Profit After Tax grew 12% YoY to ₹173 Cr, and EBITDA pre-R&D stood at ₹523 Cr, with a margin of 24%. The company saw strong growth across its businesses, particularly in the US formulation segment, which grew by 49% to ₹778 Cr. The India Branded Business also contributed positively with 7% YoY growth, reaching ₹642 Cr. Alembic Pharmaceuticals launched 3 new products in India and 7 in the US during the quarter, alongside receiving 10 ANDA approvals. The API business grew by 33% to ₹346 Cr.

Alembic Pharmaceuticals Limited announced its Unaudited Financial Results for the quarter ended June 30, 2026. The Board of Directors approved both consolidated and standalone results, along with the Limited Review Report from the statutory auditors. The filing confirms the declaration of these results following a board meeting held on August 4, 2026. Specific financial figures from the P&L tables are not included as per instructions, but the declaration of unaudited results for the specified period is the key event.

Alembic Pharmaceuticals' consolidated revenue for Q1 FY27 rose 25.7% YoY to ₹2,149.77 Cr (from ₹1,710.72 Cr) and 16.4% QoQ, comfortably ahead of management's own low-double-digit FY27 topline growth target set on the May 2026 concall. Consolidated PAT (before non-controlling interests) was ₹172.36 Cr, up 12.2% YoY but down 14.5% QoQ from ₹201.54 Cr; EPS was ₹8.80 versus ₹7.85 a year ago. There were no exceptional items this quarter or a year ago, so the YoY PAT comparison is clean — the gap versus revenue growth is a margin story, not a one-off. Consolidated net profit margin compressed to 8.05% from 9.02% a year ago, and operating margin eased to 16.18% from 16.84%, consistent with the 100-150bps EBITDA drag management flagged from scaling up the US branded business. The QoQ decline also overstates weakness: Q4FY26's ₹201.54 Cr PAT was lifted by a one-off ₹114.21 Cr deferred-tax credit that did not recur this quarter. Standalone tells a starkly different story — standalone PAT jumped 90.3% YoY to ₹196.96 Cr (from ₹103.52 Cr), EPS ₹10.02 versus ₹5.27. The gap between standalone (+90% PAT) and consolidated (+12% PAT) growth points to a subsidiary drag: the auditor's report flags one unreviewed subsidiary posting a ₹25.93 Cr net loss this quarter, consistent with the costs of the US ramp management has been guiding to. No specific Q1 FY27 consensus revenue/PAT figures turned up in search; the pre-result preview's expectation of ~₹350-360 Cr revenue and 28-30% EBITDA margin sits far below the scale of the reported numbers (₹2,149.77 Cr consolidated revenue, 16.18% OPM), suggesting that estimate referenced a sub-segment (likely the US business) rather than total company revenue — this filing discloses only one reportable segment, so a like-for-like check isn't possible. Pipeline momentum flagged pre-result continued: final USFDA approval for Prucalopride Tablets (Jul 28) and partner Natco Pharma's tentative USFDA approval for Olaparib Tablets (Jul 18). The inspection-risk flag also materialised — USFDA issued a Warning Letter to a clinical investigator (Jul 13) — though this filing gives no detail on scope or remediation. The Board separately fixed Jul 29 as the FY26 dividend record date and set the 16th AGM for Aug 5, both administrative and unrelated to this quarter's numbers. Management has not published a press-release commentary on this result in our records. Going into Q2 FY27, the swing factor for consolidated growth is whether the loss-making subsidiary narrows as the US branded ramp matures — standalone profitability is already compounding well ahead of the FY27 guidance, and consolidated growth should converge higher if that drag eases, per management's own 2-3 year path back to ~20% EBITDA margins.

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, in 1 mg and 2 mg strengths. This approval makes the company's product therapeutically equivalent to Takeda Pharmaceuticals USA Inc.'s Motegrity Tablets. Prucalopride tablets are used to treat chronic idiopathic constipation in adults. The estimated market size for these tablets was US$100 million for the twelve months ending March 2026. This marks Alembic's 225th final ANDA approval from the USFDA, contributing to their cumulative total of 245 approvals.

Alembic Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 4, 2026. The primary agenda for this meeting is to consider and approve the company's unaudited financial results for the first quarter of the fiscal year 2027, ending June 30, 2026. Following the declaration of these results, the trading window for dealing in the company's securities will reopen 48 hours after the announcement, as per the company's code of conduct.

Alembic Pharmaceuticals Limited announced that its partner, NATCO Pharma Limited, has received tentative approval from the US Food & Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg. This approval is for an Abbreviated New Drug Application (ANDA) that is therapeutically equivalent to AstraZeneca's Lynparza Tablets. Alembic will handle distribution in the U.S., while NATCO will manufacture the product. The U.S. market for Olaparib Tablets is estimated at USD 1.4 billion. This marks Alembic's 20th tentative approval from the USFDA, adding to its total of 244 ANDA approvals.

Alembic Pharmaceuticals Ltd has been informed that the USFDA has issued a Warning Letter dated July 10, 2026, to a Clinical Investigator associated with a bioequivalence study conducted at its Vadodara facility. The inspection occurred from March 3-7, 2025. The letter pertains to observations regarding the Informed Consent Form (ICF) and does not relate to data integrity. Alembic Pharma's preliminary assessment indicates no restriction on its facility's operations. The company is cooperating with the Clinical Investigator to submit a timely response. No material financial impact is identified at this stage.

Alembic Pharmaceuticals Limited has announced its 16th Annual General Meeting (AGM) will be held on Wednesday, August 5, 2026, at 4:00 p.m. IST via Video Conference/Other Audio Visual Means. The company is also providing access to the Annual Report for FY 2025-26 and the Notice convening the AGM through email to shareholders with registered email addresses and via weblinks on the company's website and stock exchanges for others. Key dates for TDS exemption, record date for final dividend, and e-voting have been set for July 29, 2026, and August 2-4, 2026, respectively. Dividend payment is scheduled on or from August 6, 2026. Shareholders are also reminded to update KYC details if not already registered.